PTA-News: MetrioPharm AG: MetrioPharm Selected by European Commission for Funding as Part of the "HERA Incubator”
• European Commission nominates MetrioPharm with Covid project "iMPact" to HERA funded projects

Wednesday, 28. July 2021 11:00

Business news for the stock market

Zürich (pta027/28.07.2021/11:00) - Zurich, July 28, 2021. MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, has been nominated to receive funding under the HERA Incubator from the European Commission under Grant Agreement number 101046182. MetrioPharm's iMPact project is one of 11 consortia and research initiatives selected to work on vaccines, therapies and other medical measures targeting the Corona virus and its mutations.

The European Commission's funding program was launched in April 2021 to support urgently needed research and development across Europe to combat the corona virus and its variants. MetrioPharm AG, as consortium leader with the project "iMPact", is one of 6 initiatives nominated by the Commission to work on drug candidates for the treatment of SARS-CoV2. In the iMPact project, MetrioPharm has joined forces with three partner companies, Catalyze, MC Toxicology Consulting and ImmunoLogik, aiming to prepare a large-scale Covid research project which will include conducting a Phase II clinical proof-of-concept study of MetrioPharm’s lead compound MP1032 against COVID-19. MP1032 has demonstrated both, strong immunomodulatory and specific antiviral properties against SARS-CoV-2 in preclinical studies.

MetrioPharm CEO Dr. Wolfgang Brysch commented, "We are very pleased with the announcement by the European Commission and the vote of confidence in our compound MP1032. The MetrioPharm team considers the decision as support for the pharmaceutical development steps already taken, and going forward for MP1032 in countering COVID-19. In view of a potential fourth wave in the fall, despite increasing vaccination rates, we should always keep in mind that better therapeutic options must be an essential part of the pandemic response. We develop our immunomodulator MP1032 to alleviate COVID-19 symptoms and shorten hospitalizations."


emitter: MetrioPharm AG
address: Bleicherweg 10, 8002 Zürich
country: Switzerland
contact person: Lia Petridou
phone: +49 30 33 84 395 53

ISIN(s): CH0107076744 (share)
stock exchanges: -
other stock exchanges: Ausserbörslicher Aktienhandel

[ source: ]

Related Links: